Cantargia AB (publ) (STO:CANTA)

Market Cap	804.26M
Revenue (ttm)	n/a
Net Income (ttm)	-171.62M
Shares Out	248.61M
EPS (ttm)	-0.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,816,712
Average Volume	11,562,390
Open	3.130
Previous Close	3.135
Day's Range	3.080 - 3.290
52-Week Range	1.000 - 4.780
Beta	1.79
RSI	62.40
Earnings Date	Aug 21, 2025

About Hess Corporation

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CANTA

Financial Performance

Financial numbers in BGN